BioCentury | Dec 15, 2014
Finance

Avanir Chronicles

...negotiations for a loan of up to $130M from HealthMed Inc. E. 3/31/00 - Grants SmithKline Beecham...
BioCentury | Apr 28, 2014
Strategy

GSK's special feeling

...Nearly 15 years after Glaxo Wellcome plc and SmithKline Beecham plc merged to form the world's largest...
BioCentury | Mar 31, 2014
Company News

Mylan, GlaxoSmithKline neurology news

...In Mylan Inc. et al v. SmithKline Beecham Corp. et al, a jury in the U.S. District...
BioCentury | Apr 15, 2013
Clinical News

Hepagene vaccine and immunotherapeutic data

...as a one-month/two dose regimen. The trial was a double-blind study of Hepagene compared to SmithKline Beecham’s...
BioCentury | Apr 15, 2013
Company News

Incyte Pharmaceuticals Inc., SmithKline deal

...molecular diagnostic discovery tools (see BioCentury, Sept. 8). Incyte Pharmaceuticals Inc. (INCY), Palo Alto, Calif. SmithKline Beecham...
BioCentury | Apr 15, 2013
Company News

Penederm, SmithKline deal

...companies will co-develop an over-the-counter product using DERM's TopiCare polymer delivery compounds with an undisclosed SmithKline Beecham...
...will generate revenues from supplying the compounds to SmithKline. Penederm Inc. (DERM), Foster City, Calif. SmithKline Beecham...
BioCentury | Apr 15, 2013
Company News

Medi-Ject, SmithKline deal

...undisclosed SmithKline compounds via MEDJ's Medi-Ject needle-free drug delivery technology. Medi-Ject Corp. (MEDJ), Minneapolis, Minn. SmithKline Beecham...
BioCentury | Apr 15, 2013
Company News

Kissei Pharmaceutical metabolic, cardiovascular news

...Servier (Paris, France) and Purdue Pharma L.P. (Norwalk, Conn.). Tranilast is in development with partner SmithKline Beecham...
BioCentury | Apr 15, 2013
Clinical News

Texas Biotech regulatory update

The FDA granted priority review status for TBX's NDA for its Novastan ( argatroban ) thrombin inhibitor. TBX and SmithKline-Beecham (Philadelphia, Penn.) last month agreed to market and co-develop Novastan in the U.S. and Canada as an...
BioCentury | Apr 15, 2013
Clinical News

SmithKline regulatory update

...in motor control. SmithKline plans to launch the product in the next couple of weeks. SmithKline Beecham...
Items per page:
1 - 10 of 760
BioCentury | Dec 15, 2014
Finance

Avanir Chronicles

...negotiations for a loan of up to $130M from HealthMed Inc. E. 3/31/00 - Grants SmithKline Beecham...
BioCentury | Apr 28, 2014
Strategy

GSK's special feeling

...Nearly 15 years after Glaxo Wellcome plc and SmithKline Beecham plc merged to form the world's largest...
BioCentury | Mar 31, 2014
Company News

Mylan, GlaxoSmithKline neurology news

...In Mylan Inc. et al v. SmithKline Beecham Corp. et al, a jury in the U.S. District...
BioCentury | Apr 15, 2013
Clinical News

Hepagene vaccine and immunotherapeutic data

...as a one-month/two dose regimen. The trial was a double-blind study of Hepagene compared to SmithKline Beecham’s...
BioCentury | Apr 15, 2013
Company News

Incyte Pharmaceuticals Inc., SmithKline deal

...molecular diagnostic discovery tools (see BioCentury, Sept. 8). Incyte Pharmaceuticals Inc. (INCY), Palo Alto, Calif. SmithKline Beecham...
BioCentury | Apr 15, 2013
Company News

Penederm, SmithKline deal

...companies will co-develop an over-the-counter product using DERM's TopiCare polymer delivery compounds with an undisclosed SmithKline Beecham...
...will generate revenues from supplying the compounds to SmithKline. Penederm Inc. (DERM), Foster City, Calif. SmithKline Beecham...
BioCentury | Apr 15, 2013
Company News

Medi-Ject, SmithKline deal

...undisclosed SmithKline compounds via MEDJ's Medi-Ject needle-free drug delivery technology. Medi-Ject Corp. (MEDJ), Minneapolis, Minn. SmithKline Beecham...
BioCentury | Apr 15, 2013
Company News

Kissei Pharmaceutical metabolic, cardiovascular news

...Servier (Paris, France) and Purdue Pharma L.P. (Norwalk, Conn.). Tranilast is in development with partner SmithKline Beecham...
BioCentury | Apr 15, 2013
Clinical News

Texas Biotech regulatory update

The FDA granted priority review status for TBX's NDA for its Novastan ( argatroban ) thrombin inhibitor. TBX and SmithKline-Beecham (Philadelphia, Penn.) last month agreed to market and co-develop Novastan in the U.S. and Canada as an...
BioCentury | Apr 15, 2013
Clinical News

SmithKline regulatory update

...in motor control. SmithKline plans to launch the product in the next couple of weeks. SmithKline Beecham...
Items per page:
1 - 10 of 760